



SHADYSIDE
HOSPITAL

5230 Centre Avenue
Pittsburgh, Pennsylvania 15232
412/622-2121

Department of Diagnostic Imaging

Writer's Direct Dial Number:

November 1, 1985

Material Licensing
U.S. Nuclear Regulatory Commission
Region #1
631 Park Avenue
King of Prussia, PA 19406

RE: Shadyside Hospital,
Pittsburgh, PA
NRC License #37-02523-01

Dear Sir:

Please find enclosed our application for amendment to our NRC License. Supporting documentation is also enclosed. Also, enclosed is a check for the amount of \$120.00, payable to the U.S. Nuclear Regulatory Commission for the amendments to our license.

Sincerely,

William J. Grego, Jr.

William J. Grego, Jr.
Vice President
Administration

WJG:ct

Nov 11 - I

Applicant	03542
Check No.	03542
Amount	\$120.00
Type of	Amendment
Date Check	11/15/85
Received By	J. Rego

8604170321 860303
REG1 LIC30
37-02523-01 PDR

U.S. NUCLEAR
REGULATORY COMMISSION
LIC. FEE MGMT. BRANCH

85 NOV 15 AM 1:46

RECEIVED

NOV 15 1985

"OFFICIAL RECORD COPY"

ML10

104601

RADIATION SAFETY COMMITTEE

The membership of this committee will consist of at least three members and will include:

1. the radiation safety officer
2. the hospital administrator or other administrative official directly responsible to the hospital administrator in the hospital's internal chain of command;
3. an authorized user for each type of use permitted by the license; and
4. a representative of the hospital's nursing staff.

The names and qualifications of the committee members will be documented in the committee's records, will be updated as necessary, and will be available for inspection by the NRC.

Item #7
1 of 3 pages
Prepared: 9/10/85
Lic. #37-02523-01

APPENDIX B

RADIATION SAFETY COMMITTEE

Responsibility:

The committee is responsible for:

1. Ensuring that all individuals who work with or in the vicinity of radioactive material have sufficient training and experience to enable them to perform their duties safely and in accordance with NRC regulations and the conditions of the license.
2. Ensuring that all use of radioactive material is conducted in a safe manner and in accordance with NRC regulations and the conditions of the license.

Duties:

The committee shall:

1. Be familiar with all pertinent NRC regulations, the terms of the license, and information submitted in support of the request for the license and its amendments.
2. Review the training and experience of all individuals who use radioactive materials (including physicians, technologists, physicists, and pharmacists) and determine that their qualifications are sufficient to enable them to perform their duties safely and in accordance with NRC regulations of the license.

3. Establish a program to ensure that all individuals whose duties may require them to work in the vicinity of radioactive material (e.g., nursing, security and house-keeping personnel) are properly instructed as required by 19.12 of 10 CFR Part 19.

4. Review and approve all requests for use of radioactive material within the institution.

5. Prescribe special conditions that will be required during a proposed use of radioactive material such as requirements for bioassays, physical examinations of users, and special monitoring procedures.

6. Review the entire radiation safety program at least annually to determine that all activities are being conducted safely and in accordance with NRC regulations and the conditions of the license. The review shall include an examination of all records, reports from the radiation safety officer, results of NRC inspections, written safety procedures, and the adequacy of the institution's management control system.

7. Recommend remedial action to correct any deficiencies identified in the radiation safety program.

8. Maintain written records of all committee meetings, actions recommendations, and decisions.

Item #7
2 of 3 pages
Prepared: 9/10/85
Lic. #37-02523-01

9. Ensure that the byproduct material license is amended, when necessary, prior to any changes in facilities, equipment, policies, procedures, and personnel, as specified in the license.

Meeting Frequency:

The Radiation Safety Committee shall meet as often as necessary to conduct its business but not less than once in each calendar quarter.

Item #7
3 of 3 pages
Prepared: 9/10/85
Lic. #37-02523-01

NAME OF AUTHORIZED USER

AUTHORIZATION

Mark H. Wholey, M.D.

All

T.S. Danowski, M.D.

- In Vitro studies
- Iodine-131 as sodium iodine for thyroid imaging and thyroid uptake studies
- Iodine-131 for treatment of hyperthyroidism and cardiac dysfunction

Yong Deok Kim, M.D.

- Group VI

Gary G. Winzelberg, M.D.

- Groups I, II and III
- In Vitro studies
- Xenon-133
- Iodine-131 as iodide for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma
- Phosphorous-32 as soluble phosphate for treatment of polycythemia vera, leukemia and bone metastases
- Phosphorous-32 as colloidal chromic phosphate for intracavitary treatment of malignant effusions

Ingrid Naugle, M.D.

- Groups I, II and III
- Xenon-133
- Iodine-131 as iodine for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma

Kevin R. O'Hara, M.D.

- Groups I and II

All users indicated are on current NRC License #37-02523-01.

Please note that we have requested the use of P-32 colloidal chromic phosphate for Dr. Gary Winzelberg. For training and experience for this isotope, refer to attached Supplement B.

Item #8
1 of 1 page
Prepared: 9/10/85
Lic. #37-02523-01